WUXI, China, May 22, 2025 /PRNewswire/ -- Zhao Jianjun, Mayor of Wuxi City, China, recently led a municipal delegation to Thailand to strengthen bilateral engagement and advance cooperation in the areas of cultural tourism, modern service industries, and advanced manufacturing.
According to publicly available data on international cultural tourism, two-way travel between China and Thailand rose by 160% in 2024 compared to 2019, following the enactment of a mutual visa waiver agreement. Taihu Yuantouzhu Scenic Area, one of Wuxi's key destinations, has seen a marked increase in visitation from Thai travelers. During the visit, several Thai cultural tourism organizations entered into cooperative agreements with Wuxi Cultural Tourism Development Group, formalizing plans for future joint initiatives.
A spokesperson for the group who participated in the visit stated that the two sides have committed to implementing 10 cultural exchange initiatives. These include youth artist residency programs and reciprocal exhibitions featuring traditional intangible cultural heritage skills. In addition, plans are underway to showcase Taihu-themed cultural and creative works at the upcoming China-ASEAN Expo Tourism Exhibition.
In advance of the delegation's arrival, a cultural exhibition titled Taihu Lake Lake Scenery • Silk Road Feelings opened on May 18, 2025, at the Queen Sirikit National Convention Center in Bangkok. Featuring contributions from prominent artists participating in the Belt and Road Initiative, the exhibit presents more than 40 works—ranging from traditional Chinese ink to oil paintings—depicting the natural beauty of Taihu Lake and the broader Jiangnan region. The exhibition offers an immersive cultural experience that celebrates Wuxi's heritage and the artistic legacy of southern China.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Global Times Online: Wuxi and Thailand Deepen Cultural and Tourism Ties, Highlighting the Scenic Appeal of Taihu Lake
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
